News | Hypertension | November 12, 2015

With Help from Pharmacists, Better Blood Pressure Cost $22

Multi-state study determines most cost-effective collaboration efforts for minority and low-income populations

pharmacist-physician collaboration, high blood pressure control, minority and low-income populations

November 12, 2015 — A pharmacist-physician collaborative effort to control blood pressure among a diverse group of patients was considered cost-effective, according to new research in the American Heart Association’s journal Hypertension. Researchers found that a $22 price tag increased the hypertension control rate by 1 percent.

“Previous studies have demonstrated the cost-effectiveness of collaborative hypertension control programs. However, most lacked minority and low-income populations,” said Linnea Polgreen, Ph.D., lead researcher and an assistant professor in the Department of Pharmacy Practice and Science at the University of Iowa.

In this study of 625 patients, 38 percent were black, 14 percent were Hispanic and 49 percent had an annual household income less than $25,000.

Costs were assigned to medications, and pharmacist and physician time. Cost-effectiveness ratios were calculated based on changes in blood pressure measurements and hypertension control rates.

Participants were from 32 medical offices in 15 states, and all had uncontrolled high blood pressure, defined as systolic pressure of 140 mm Hg or higher, or diastolic of 90 mm Hg or higher. Among those with diabetes or chronic kidney disease, blood pressure was considered high at or above 130 mm Hg systolic or 80 mm Hg diastolic.

Patients were randomized to a pharmacist-physician intervention program for nine months or to a control group receiving usual care.

The intervention included a clinical pharmacist reviewing patients’ medical records, contacting them by phone and regular face-to-face visits. The pharmacist created a care plan and made recommendations to the physician to adjust medication. In this study, the pharmacist worked in the medical office and met face-to-face with physicians.

After nine months of the collaborative intervention:

  • Average systolic blood pressure was 6.1 mm Hg lower;
  • Average diastolic pressure was 2.9 mm Hg lower; and
  • Hypertension control rate was 43 percent, compared to 34 percent in the control group.

“Patients in the intervention groups had higher costs than those in the control group, but these costs were mostly due to higher prescription drug costs – not the cost of the pharmacist’s time,” Polgreen said. “On average the pharmacist spent about two hours per patient over the course of the study.

“An unexpected finding was that the intervention group had fewer physician visits, thus saving physician time for other, more complex patient health problems,” Polgreen added.

She noted that even for patients who regularly take their medication, controlling blood pressure requires monitoring. “In many clinics, especially in low-income areas, physicians do not have the resources to monitor these patients.”

An estimated one-third of American adults have high blood pressure, which is a major risk factor for heart disease and stroke.

While the clinics in this study all had an in-house pharmacist, Polgreen said people with uncontrolled high blood pressure may want to ask their physician if they have other team members in their office who could assist with managing blood pressure.

Co-authors are Barry Carter, Pharm.D.; Jayoung Han, Ph.D.; Gail Ardery, Ph.D.; Christopher Coffey, Ph.D.; Elizabeth Chrischilles, Ph.D.; and Paul James, M.D.

Author disclosures are on the manuscript.

The study was funded by grants from the National Institutes of Health.

For more information: www.heart.org

Related Content

Lexington Begins HeartSentry Clinical Trial
News | Clinical Study | February 20, 2018
February 20, 2018 – Lexington Biosciences, Inc., a development-stage medical device company, announced the commenceme
Endologix Completes Patient Enrollment in the ELEVATE IDE Clinical Study
News | Clinical Study | February 06, 2018
February 6, 2018 – Endologix, a developer and marketer of treatments for aortic disorders, announced the completion o
12-Month Results from Veryan Medical's MIMICS-2 IDE Study Presented at LINC
News | Clinical Study | February 01, 2018
February 1, 2018 – Thomas Zeller (Bad Krozingen, Germany) presented the 12-month results from Veryan Medical’s MIMICS
LimFlow Completes U.S. Feasibility Study Enrollment, Receives FDA Device Status
News | Clinical Study | February 01, 2018
February 1, 2018 –  LimFlow SA, developer of minimally-inv
ESC 2017 late breaking trial hot line study presentations.
News | Clinical Study | September 12, 2017
September 12, 2017 – The European Society of Cardiology (ESC) Congress 2017 includes several Hot Line Late-breaking C
U.K., NHS studies, weekend effect, hospital admission, atrial fibrillation, heart failure
News | Clinical Study | June 28, 2016
New research shows patients admitted to National Health Service (NHS) hospitals in the United Kingdom for atrial...
stroke risk
News | Clinical Study | August 28, 2015
Most people assume strokes only happen to octogenarians, but recent evidence suggests that survivors of childhood can
Overlay Init